Skip to main content

Table 3 Vaccine prices required to achieve cost-effectiveness a

From: Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis

Risk group

Cost per DALY (excluding asthma)

Cost per DALY (including asthma)

Palivizumab price to achieve cost-Effectiveness (including asthma)

% decrease in Palivizumab Price

50 mg

Vial b

100 mg

Vial c

CHD

$266,020

$218,968

$278

$512

46.5%

CLD

$472,139

$287,057

$270

$497

48.1%

<29

$585,537

$226,900

$329

$605

36.8%

29–32

$685,961

$347,593

$237

$436

54.5%

33–36

$2,092,809

$1,149,584

$87

$160

83.3%

No risk

$7,503,953

$3,023,294

$31

$57

94.0%

  1. a based on threshold of $105,986 per averted DALY and 2945 annual hospitalizations in children under two
  2. b current price (excluding VAT) of $520 per vial
  3. c current price (excluding VAT) of $959 per vial